TOTUM-854

Arterial hypertension, the first cardiovascular risk factor

Arterial hypertension (AHT) is the world’s most prevalent chronic disease and the leading cause of premature death. It affects all countries, regardless of their level of development.

In the long term, AHT weakens the arteries and promotes the onset of serious diseases, predominantly heart attacks, strokes, peripheral arterial diseases and kidney failure. It is the primary cardiovascular risk factor in the world.

 

Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; Prise en charge de l’hypertension artérielle de l’adulte, Recommandation de bonne pratique, HAS, 2016 www.has-sante.fr/jcms/c_2059286/fr/prise-en-charge-de-l-hypertension-arterielle-de-l-adulte

Key Figures

First chronic disease in the world

1.13

billion people worldwide with arterial hypertension in 2015. 30 to 45% of adults are hypertensive.

Source: 2018 ESC/ESH Guidelines for the management of arterial hypertension.

Hypertension thresholds

140

/90 mmHG, is the defined threshold for arterial hypertension in Europe. In the United States, the threshold value starts at 130/80 mmHg.

Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

TOTUM-854, to reduce elevated blood pressure, a risk factor for cardiovascular diseases

TOTUM-854 is a unique and patented combination of plant extracts, designed to reduce arterial blood pressure, in people with a moderate elevation in blood pressure.

The TOTUM-854 program aims at obtaining a health claim related to blood pressure reduction, a risk factor for cardiovascular diseases, in Europe and North America.

TOTUM-854 could be a new opportunity in a  1-billion people market worldwide. Currently no non-drug product with solid clinical evidence nor health claims for blood pressure reduction is available.

A clinical Phase II pending, to reduce blood pressure

A Phase II clinical study, randomized, placebo-controlled, double blind, will include 100 subjects with a moderate elevation of blood pressure.

Its primary objective will be the reduction of systolic blood pressure. Its launch is planned late 2020, for the first results expected at the beginning of 2022. 

Intellectual property

Patent applications have been filed for TOTUM-854 in more than 60 countries, including key territories: Europe, USA, Canada, China, Russia, Japan, Brazil, Australia.

The patent was granted in France in 2014, in the United States in 2018, in Europe in 2019 (39 countries), in Russia in 2020 with a high level of protection.

-